Reduced IFNL1 and/or IFNL2, but not IFNL3 is associated with worse outcome in patients with COVID-19.

IF 3.4 3区 医学 Q3 IMMUNOLOGY Clinical and experimental immunology Pub Date : 2024-11-12 DOI:10.1093/cei/uxae047
Elena Woods, Adriana Mena, Sophie Sierpinska, Emily Carr, Sttar Bioresource, Richard Hagan, John Crowley, Colm Bergin, David Clark, Caroline Brophy, Derek Macallan, Clair M Gardiner
{"title":"Reduced IFNL1 and/or IFNL2, but not IFNL3 is associated with worse outcome in patients with COVID-19.","authors":"Elena Woods, Adriana Mena, Sophie Sierpinska, Emily Carr, Sttar Bioresource, Richard Hagan, John Crowley, Colm Bergin, David Clark, Caroline Brophy, Derek Macallan, Clair M Gardiner","doi":"10.1093/cei/uxae047","DOIUrl":null,"url":null,"abstract":"<p><p>The recent pandemic was caused by the emergence of a new human pathogen, SARS-CoV-2. While the rapid development of many vaccines provided an end to the immediate crisis, there remains an urgent need to understand more about this new virus and what constitutes a beneficial immune response in terms of successful resolution of infection. Indeed, this is key for development of vaccines that provide long lasting protective immunity. The interferon lambda (IFNL) family of cytokines are produced early in response to infection and are generally considered anti-viral and beneficial. However, data regarding production of IFNL cytokines in coronavirus disease 2019 (COVID-19) patients is highly variable, and generally from underpowered studies. In this study, we measured all three IFNL1, IFNL2, and IFNL3 cytokines in plasma from a well characterized, large COVID-19 cohort (n = 399) that included good representation from patients with a more indolent disease progression, and hence a beneficial immune response. While all three cytokines were produced, they differed in both the frequency of expression in patients, and the levels produced. IFNL3 was produced in almost all patients but neither protein level nor IFNL3/IFNL4 single nucleotide polymorphisms were associated with clinical outcome. In contrast, both IFNL1 and IFNL2 levels were significantly lower, or absent, in plasma of patients that had a more severe disease outcome. These data are consistent with the concept that early IFNL1 and IFNL2 cytokine production is protective against SARS-CoV-2 infection.</p>","PeriodicalId":10268,"journal":{"name":"Clinical and experimental immunology","volume":" ","pages":"300-307"},"PeriodicalIF":3.4000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11557148/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and experimental immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cei/uxae047","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The recent pandemic was caused by the emergence of a new human pathogen, SARS-CoV-2. While the rapid development of many vaccines provided an end to the immediate crisis, there remains an urgent need to understand more about this new virus and what constitutes a beneficial immune response in terms of successful resolution of infection. Indeed, this is key for development of vaccines that provide long lasting protective immunity. The interferon lambda (IFNL) family of cytokines are produced early in response to infection and are generally considered anti-viral and beneficial. However, data regarding production of IFNL cytokines in coronavirus disease 2019 (COVID-19) patients is highly variable, and generally from underpowered studies. In this study, we measured all three IFNL1, IFNL2, and IFNL3 cytokines in plasma from a well characterized, large COVID-19 cohort (n = 399) that included good representation from patients with a more indolent disease progression, and hence a beneficial immune response. While all three cytokines were produced, they differed in both the frequency of expression in patients, and the levels produced. IFNL3 was produced in almost all patients but neither protein level nor IFNL3/IFNL4 single nucleotide polymorphisms were associated with clinical outcome. In contrast, both IFNL1 and IFNL2 levels were significantly lower, or absent, in plasma of patients that had a more severe disease outcome. These data are consistent with the concept that early IFNL1 and IFNL2 cytokine production is protective against SARS-CoV-2 infection.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
IFNL1 和/或 IFNL2(而非 IFNL3)的降低与 COVID-19 患者的预后较差有关。
最近的大流行是由一种新的人类病原体 SARS-CoV-2 引起的。虽然许多疫苗的快速开发结束了这场直接危机,但人们仍然迫切需要更多地了解这种新病毒,以及什么是成功解决感染的有益免疫反应。事实上,这是开发可提供长期保护性免疫的疫苗的关键。λ干扰素(IFNL)系列细胞因子在感染早期就会产生,通常被认为是抗病毒和有益的。然而,有关 COVID-19 患者 IFNL 细胞因子产生情况的数据变化很大,而且一般都是来自幂等不足的研究。在这项研究中,我们测量了一个特征明确、规模庞大的 COVID-19 患者群(人数=399)血浆中的所有三种 IFNL1、IFNL2 和 IFNL3 细胞因子,其中包括病情发展较为缓和的患者,因此他们的免疫反应是有益的。虽然所有三种细胞因子都会产生,但它们在患者体内的表达频率和产生水平都有所不同。几乎所有患者都会产生 IFNL3,但蛋白水平和 IFNL3/IFNL4 SNPs 都与临床结果无关。相比之下,在病情较重的患者血浆中,IFNL1 和 IFNL2 的水平明显较低或不存在。这些数据与早期 IFNL1 和 IFNL2 细胞因子的产生对 SARS-CoV-2 感染具有保护作用的观点一致。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
8.40
自引率
2.20%
发文量
101
审稿时长
3-8 weeks
期刊介绍: Clinical & Experimental Immunology (established in 1966) is an authoritative international journal publishing high-quality research studies in translational and clinical immunology that have the potential to transform our understanding of the immunopathology of human disease and/or change clinical practice. The journal is focused on translational and clinical immunology and is among the foremost journals in this field, attracting high-quality papers from across the world. Translation is viewed as a process of applying ideas, insights and discoveries generated through scientific studies to the treatment, prevention or diagnosis of human disease. Clinical immunology has evolved as a field to encompass the application of state-of-the-art technologies such as next-generation sequencing, metagenomics and high-dimensional phenotyping to understand mechanisms that govern the outcomes of clinical trials.
期刊最新文献
A novel mouse model of myositis-associated interstitial lung disease was established by using TLR9 agonist combined with muscle homogenate. Past, Present and Future of Phase 3 Vaccine Trial Design: Rethinking Statistics for the 21st Century. Immunomodulatory effects of HYCO-3, a dual action CO-releaser/Nrf2 activator. Reduced IFNL1 and/or IFNL2, but not IFNL3 is associated with worse outcome in patients with COVID-19. A homogeneous bioluminescent inhibition immunoassay to detect anti-interferon gamma antibodies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1